We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Revolutionary Blood Test Enables Early Detection of Coronary Heart Disease

By LabMedica International staff writers
Posted on 01 Mar 2023
Print article
Image: PrecisionCHD is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (Photo courtesy of Cardio Diagnostics)
Image: PrecisionCHD is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (Photo courtesy of Cardio Diagnostics)

Cardiovascular disease (CVD) remains one of the leading causes of death globally, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. Now, a new test aids in the early detection of coronary heart disease to better enable the management of this condition for preventing a symptomatic event such as a heart attack.

Cardio Diagnostics Holdings Inc. (Chicago, IL, USA) has launched PrecisionCHD, the first integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Using epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers along with a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points, PrecisionCHD detects coronary heart disease with better than 75% sensitivity in both men and women.

Importantly, PrecisionCHD is accompanied by a provider-only Actionable Clinical Intelligence platform, which maps a patient’s unique biomarker profile onto modifiable risk factors like diabetes, hypertension, hypercholesterolemia, and smoking, which are considered to be critical drivers of coronary heart disease. The non-invasive, simple test offers healthcare providers a complement to traditional CHD diagnostic solutions and provides an informative, personalized patient report of CHD status.

“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

Related Links:
Cardio Diagnostics Holdings Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.